Two cases of neural tube defects with dolutegravir use at conception in south Brazil

dc.contributor.author	Kreitchmann, Regis	pt_BR
dc.contributor.author	Oliveira, Fernando Rocha de	pt_BR
dc.contributor.author	Sprinz, Eduardo	pt_BR
dc.date.accessioned	2022-04-07T04:48:29Z	pt_BR
dc.date.issued	2021	pt_BR
dc.identifier.issn	1413-8670	pt_BR
dc.identifier.uri	http://hdl.handle.net/10183/236731	pt_BR
dc.description.abstract	Dolutegravir (DTG) is amongst the most prescribed antiretrovirals worldwide and is recommended as first line regimen in most HIV treatment guidelines. Its use, although infrequently, had been associated to an increased chance of neural tube defects (NTD) in Botswana, Africa. Herein we describe two cases of NTD in women who conceived while taking DTG as part of their antiretroviral treatment in the city of Porto Alegre, Brazil.	en
dc.format.mimetype	application/pdf	pt_BR
dc.language.iso	eng	pt_BR
dc.relation.ispartof	The Brazilian journal of infectious diseases. Salvador. Vol. 25, no. 2 (Mar./Apr. 2021), 101572, 4 p.	pt_BR
dc.rights	Open Access	en
dc.subject	COVID-19	en
dc.subject	HIV	pt_BR
dc.subject	Gravidez	pt_BR
dc.subject	Neural tube defects	en
dc.subject	Pregnancy	en
dc.subject	Defeitos do tubo neural	pt_BR
dc.subject	Porto Alegre (RS)	pt_BR
dc.subject	Dolutegravir	en
dc.title	Two cases of neural tube defects with dolutegravir use at conception in south Brazil	pt_BR
dc.type	Artigo de periódico	pt_BR
dc.identifier.nrb	001137454	pt_BR
dc.type.origin	Nacional	pt_BR

This item is licensed under a Creative Commons License